SPAC Market Review – February 2023

by | Mar 6, 2023

The SPAC market continues its slow, painful regression back towards SPAC normalcy (i.e. pre-SPAC mania). The challenges remain the same as SPACs continue to liquidate, redemptions remain at (no longer?) shockingly high levels, some try to extend, and few try to come to market. With a bevy of SPACs set to liquidate – over 50 have deadlines in March 2023 – over the next few months perhaps a thinner market can bring some normalcy back, though there is little to support any enthusiasm in the vehicle at this point.

Below, is a run down of the SPAC market activity for February 2023 — including an increasing pace and amount of deSPAC bankruptcies.

SPAC Mergers

Despite the ongoing negativity in the sector, sponsors are still incentivized to get to business combination agreements, thus merger activity continues despite a dried up SPAC financing market. Another 17 DAs were announced in February, in line with recent activity. However just one deal, Pono’s combination with SBC Medical, is valued at > $1B.

17 SPAC deals announced in February, but only Pono’s is valued over $1B.

DeSPAC Bankruptcies

We spoke about this in last month’s review, and the activity is only heating up. Our friends at Bloomberg provided a nice overview recently of the quick bankruptcy trend facing DeSPACs on the heels of Starry Group (STRY) becoming the latest DeSPAC to file so soon after its trading debut.

Source: Bloomberg

No doubt DeSPACs are reeling. Who could be next to potentially file for bankruptcy? Take a look at the last trading prices for DeSPACs in the last 6 months alone. There are 20 SPACs that are trading at $2.50 or less, and just six DeSPACs in the last 6mos are trading above the original SPAC offer price of $10. We wouldn’t be surprised to see more cheap M&A or companies that won’t be able to survive without additional capital.

Lowest Trading SPACs from DeSPACs in the Last 6 Months

Source: Boardroom Alpha

SPAC IPOs See Uptick

The SPAC IPO market is (somewhat open) and February was the most active month of new issuance since May ’22. Overall 5 deals priced for a total of $433M. Size, however, remains on the smaller end with just two of the 5 deals pricing over $100M. SilverBox Corp III and Pono Capital Three were the two largest at $120M and $115M, respectively, and also represent the third in their respective line of SPACs from the sponsors.

February 2023 SPAC IPOs

The Great SPAC Maturity Wall

At long last we have finally hit March 2023, the month where SPACs go to die. While numerous SPACs have kicked the can down the road via extension, liquidated early, or found merger targets – we are still left with 50+ SPACs that are set to expire this month. That is WELL below the ~150 that we were staring at last year. All the SPAC extension activity as resulted in a much more evenly distributed maturity schedule, but one that is likely to wreak liquidation havoc this summer as ~150 SPACs will be set to come due from June-August.

Source: Boardroom Alpha

SPAC Liquidations, once a a surprise event, are now humming along at a steady pace. Following the insane jump in December 2022 due to the early liqudation craze spurred by the excise tax, SPACs are now liquidating at a much calmer cadence. 17 liquidated in February while another 18 have already indicated that they will liquidate in March.

Source: Boardroom Alpha

DeSPAC’ing

DeSPACs ticked up in Feb, with 12 closings finally getting across the finish line. The story remains largely the same at the SEC – a backlog and long review times continue to push merger timelines longer and longer.

Recent Analysis

Daily SPAC Update – May 4, 2026

Blueport + SingAuto and Galaxyedge + Rongcheng Group Deals announced late Friday. Pono Capital Four separate trading. Gigcapital 7 non-redemption agreement.

Weekly Boardroom & Executive Moves: May 1, 2026

This week, significant leadership changes occurred across several companies facing financial difficulties. Abbott Laboratories (ABT) and Agilon Health Inc (AGL) appointed new board members and executives amidst high activist risks and declining TSRs. Accuray Inc (ARAY) and ALT5 Sigma Corp (ALTS) also saw key executive departures and appointments as they navigate substantial TSR declines. These shifts highlight the ongoing challenges and strategic redirections needed to stabilize operations and improve shareholder value.

Daily SPAC Update – May 1, 2026

Two SPAC IPOs launched today, raising a total of $500 million. CH4 Natural Solutions Acquisition Corp (MTNE) secured $300 million, while Quantum Leap Acquisition Corp (QLEP) raised $200 million. Today, 2 SPAC IPOs raised $500M, led by CH4 Natural Solutions (MTNE) at $300M. This follows a surge of activity at the end of April.

Daily SPAC Update – April 30, 2026

Today, six SPACs debuted, raising a total of $965 million. General Catalyst Global Resilience Merger Corp (GCGR) led the pack with $350 million, followed by RRE Ventures Acquisition Corp. (RREV) at $250 million. Month-to-date, SPAC IPOs total 16, bringing in $2.65 billion, compared to 11 IPOs last month that raised $1.72 billion.

Daily SPAC Update – April 29, 2026

Collective Acquisition Corp. II (CAII) launched its $220 million IPO today, targeting high-potential sectors like technology and healthcare. In executive moves, Roger Bendelac was appointed CEO of both Drugs Made in America Acquisition Corp (DMAA) and Drugs Made in America Acquisition II Corp (DMII), with Saleem Elmasri as CFO. Meanwhile, General Purpose Acquisition Corp (GPAC) saw a significant decline of 22.9%, closing at $9.96, while Aimei Health Technology Co Ltd (AFJK) gained 2.7% to $46.12.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.